

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10525781	
	Filing Date		2005-09-20	
	First Named Inventor	Caires et al.		
	Art Unit	1621		
	Examiner Name	Marialouisa Lao		
	Attorney Docket Number	APA-PT005		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10525781
Filing Date	2005-09-20
First Named Inventor	Caires et al.
Art Unit	1621
Examiner Name	Marialouisa Lao
Attorney Docket Number	APA-PT005

1	BARBOSA et al., Biphosphinic palladacycle complex mediates lysosomal-membrane permeabilization and cell death in K562 leukaemia cells - European Journal of Pharmacology 542 (2006) 37-47	<input type="checkbox"/>
2	BINCOLETTTO et al., Chiral cyclopalladated complexes derived from N,N-dimethyl-1-phenethylamine with bridging bis (diphenylphosphine) ferrocene ligand as inhibitors of the cathepsin B activity and as antitumoral agents - Bioorganic & Medicinal Chemistry 13 (2005) 3047-3055	<input type="checkbox"/>
3	CAIRES, A.C.F., Recent Advances Involving Palladium (II) Complexes for the Cancer Therapy - Anti-Cancer Agents in Medicinal Chemistry, 2007, Vol. 7, No. 5, pgs. 1-8 - 2007 Bentham Science Publishers Ltd.	<input type="checkbox"/>
4	RODRIGUES et al., Cyclopalladated Compounds As Chemotherapeutic Agents: Antitumor Activity Against A Murine Melanoma Cell Line - Int. J. Cancer: 107, 498-504 (2003)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.